V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220017611 | 220014564 | 1.6 | null | Curative (C) | 2014-10-08 | 2014-10-11 | BOSUTINIB | 2 | N | 220031962 | BOSUTINIB |
| 220017612 | 220022105 | 1.41 | null | null | 2017-08-29 | 2017-08-30 | ATG + Busulfan + Fludarabine | null | null | 220031971 | ATG + BUSULFAN + FLUDARABINE |
| 220017613 | 220022105 | 0 | null | Disease modification (D) | 2017-05-31 | 2018-01-21 | AML Int Guide ADE 8+3+5 (2) | N | N | 220031971 | ADE |
| 220017614 | 220008427 | 1.57 | 95.2 | Curative (C) | 2014-04-28 | 2014-05-05 | Triple / Double Intrathecal Therapy | N | N | 220031997 | TRIPLE INTRATHECAL |
| 220017615 | 220008428 | 1.65 | 61.5 | Curative (C) | null | 2016-01-02 | ATG + Busulfan + Fludarabine | N | N | 220031998 | ATG + BUSULFAN + FLUDARABINE |
| 220017616 | 220008430 | null | 46 | Curative (C) | 2017-09-11 | 2017-09-11 | BOSUTINIB | 2 | N | 220032004 | BOSUTINIB |
| 220017617 | 220017963 | 1.56 | 104.9 | Disease modification (D) | 2017-08-15 | 2017-08-19 | Cyclophosphamide TBI Allograft | null | N | 220032005 | CYCLOPHOSPHAMIDE |
| 220017618 | 220008431 | 1.78 | 84.8 | Curative (C) | 2017-11-08 | 2018-02-12 | Idarubicin+Tretinoin Spanish Crse4 | 02 | N | 220032007 | IDARUBICIN + TRETINOIN |
| 220017620 | 220014570 | null | 118.5 | Curative (C) | 2016-07-30 | 2016-07-30 | RUXOLITINIB | 2 | N | 220032025 | RUXOLITINIB |
| 220017621 | 220008438 | 1.84 | 52.2 | Curative (C) | 2015-05-05 | 2015-06-23 | Cyclophosphamide TBI Allograft | N | N | 220032027 | CYCLOPHOSPHAMIDE |
| 220017622 | 220008440 | 1.8 | 86 | Curative (C) | 2017-08-08 | 2017-08-10 | ATG + Busulfan + Fludarabine | N | N | 220032029 | ATG + BUSULFAN + FLUDARABINE |
| 220017623 | 220008442 | null | 60 | Curative (C) | 2016-12-18 | 2016-12-18 | Triple Intrathecal | 2 | N | 220032039 | TRIPLE INTRATHECAL |
| 220017624 | 220014576 | 1.65 | 93.4 | Disease modification (D) | null | 2017-11-18 | Cyclophosphamide+Fludara+TBI Allo | N | N | 220032041 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220017625 | 220008446 | 1.81 | 75 | null | 2014-09-29 | 2014-11-27 | Triple / Double Intrathecal Therapy | N | N | 220032050 | TRIPLE INTRATHECAL |
| 220017626 | 220008448 | 1.56 | 70.7 | Palliative (P) | 2017-07-23 | 2017-07-23 | Idarubicin+Tretinoin Spanish Crse2 | N | N | 220032050 | IDARUBICIN + TRETINOIN |
| 220017627 | 220008451 | 1.54 | 62.3 | Curative (C) | 2015-01-27 | 2015-02-11 | CYCLOPHOSPHAMIDE | Y | null | 220032056 | CYCLOPHOSPHAMIDE |
| 220017628 | 220008452 | null | 68.5 | Disease modification (D) | null | 2013-03-04 | Triple Intrathecal | 02 | N | 220032058 | TRIPLE INTRATHECAL |
| 220017630 | 220008456 | 1.64 | null | Disease modification (D) | 2017-10-10 | 2017-10-10 | Triple Intrathecal | 02 | N | 220032064 | TRIPLE INTRATHECAL |
| 220017631 | 220008458 | 1.64 | 60.3 | null | 2015-01-08 | 2015-01-09 | Idarubicin+Tretinoin Spanish Crse4 | Y | null | 220032067 | IDARUBICIN + TRETINOIN |
| 220017632 | 220008458 | 1.86 | 67.8 | Curative (C) | 2017-06-04 | 2017-07-15 | FLAG | 02 | N | 220032067 | FLAG |
| 220017633 | 220019867 | 1.59 | 52.5 | Curative (C) | 2015-12-02 | 2015-12-09 | ATG + Busulfan + Fludarabine | N | N | 220032085 | ATG + BUSULFAN + FLUDARABINE |
| 220017634 | 220008462 | 1.71 | 68 | null | 2015-12-26 | 2015-12-28 | Triple / Double Intrathecal Therapy | N | N | 220032087 | TRIPLE INTRATHECAL |
| 220017635 | 220008465 | 1.66 | 49.8 | Curative (C) | 2014-12-24 | 2016-03-05 | CYCLOPHOSPHAMIDE | N | N | 220032105 | CYCLOPHOSPHAMIDE |
| 220017636 | 220014588 | 1.78 | 28.5 | Curative (C) | 2013-10-05 | 2013-10-09 | FLAG | 02 | null | 220032108 | FLAG |
| 220017637 | 220014590 | 1.68 | 77.6 | Curative (C) | 2014-01-23 | 2014-01-25 | AML Int Guide ADE 10+3+5 (1) | N | N | 220032113 | ADE |
| 220017638 | 220008481 | 1.25 | 85.7 | Curative (C) | 2017-09-15 | 2017-09-15 | Methotrexate intrathecal | N | N | 220032113 | METHOTREXATE INTRATHECAL |
| 220017639 | 220008483 | 1.67 | 118.5 | Disease modification (D) | 2014-05-15 | 2014-10-04 | Methotrexate intrathecal | N | N | 220032121 | METHOTREXATE INTRATHECAL |
| 220017640 | 220008484 | 1.84 | 60 | Curative (C) | null | 2013-12-30 | Methotrexate intrathecal | N | N | 220032126 | METHOTREXATE INTRATHECAL |
| 220017641 | 220008486 | 1.77 | 99.5 | Neo-adjuvant (N) | 2017-01-24 | 2017-04-16 | Idarubicin+Tretinoin Spanish Crse4 | N | N | 220032131 | IDARUBICIN + TRETINOIN |
| 220017642 | 220008488 | 1.69 | 0 | Curative (C) | 2017-11-29 | 2017-11-30 | BOSUTINIB | N | N | 220032142 | BOSUTINIB |
| 220017643 | 220008489 | 1.83 | 90 | Curative (C) | 2014-03-26 | 2014-03-30 | FLAG | N | N | 220032147 | FLAG |
| 220017644 | 220014596 | 1.84 | 73.6 | null | 2018-01-05 | 2018-01-13 | BOSUTINIB | N | N | 220032149 | BOSUTINIB |
| 220017645 | 220008493 | 1.7 | 82 | Curative (C) | 2014-04-27 | 2014-05-10 | CYCLOPHOSPHAMIDE | N | N | 220032156 | CYCLOPHOSPHAMIDE |
| 220017647 | 220008500 | 1.72 | null | Curative (C) | 2013-05-07 | 2014-06-08 | Triple Intrathecal | null | N | 220032158 | TRIPLE INTRATHECAL |
| 220017648 | 220008503 | 1.67 | null | Curative (C) | 2013-08-27 | 2013-08-28 | Triple / Double Intrathecal Therapy | 02 | N | 220032159 | TRIPLE INTRATHECAL |
| 220017649 | 220017985 | 0 | 122 | Curative (C) | 2015-11-24 | 2015-11-24 | Triple / Double Intrathecal Therapy | N | N | 220032164 | TRIPLE INTRATHECAL |
| 220017651 | 220017986 | 1.65 | 13.7 | Curative (C) | 2014-05-16 | 2014-09-07 | RUXOLITINIB | N | N | 220032170 | RUXOLITINIB |
| 220017652 | 220008512 | null | 66.4 | Disease modification (D) | 2017-12-30 | 2018-01-05 | AML16 DA 3+10 | 2 | N | 220032175 | AML16 TRIAL |
| 220017653 | 220008514 | 1.57 | 63.2 | Curative (C) | 2019-01-14 | 2019-01-23 | BOSUTINIB | 02 | N | 220032181 | BOSUTINIB |
| 220017654 | 220008517 | 1.69 | 83.7 | null | 2014-06-29 | 2014-07-02 | RUXOLITINIB | N | Y | 220032200 | RUXOLITINIB |
| 220017655 | 220008517 | 1.84 | null | Curative (C) | 2016-01-16 | 2016-01-16 | ADE 8+3+5 | Y | N | 220032200 | ADE |
| 220017656 | 220008518 | 1.77 | 56 | Curative (C) | null | 2019-02-22 | BOSUTINIB | N | null | 220032218 | BOSUTINIB |
| 220017657 | 220008522 | 0 | 13.4 | Disease modification (D) | 2015-10-02 | 2015-10-02 | AML16 DA 3+8 | 2 | N | 220032225 | AML16 TRIAL |
| 220017658 | 220014611 | 1.03 | 54.6 | Curative (C) | 2014-06-12 | 2014-10-03 | AML Int Guide ADE 8+3+5 (2) | 2 | N | 220032225 | ADE |
| 220017659 | 220014612 | null | 69.9 | null | 2017-05-16 | 2017-07-28 | FLAG | N | N | 220032227 | FLAG |
| 220017660 | 220014612 | 1.66 | 86.8 | Adjuvant (A) | 2016-01-01 | 2016-01-01 | RUXOLITINIB | 02 | N | 220032227 | RUXOLITINIB |
| 220017661 | 220008527 | 1.57 | 39.2 | Curative (C) | 2015-10-19 | 2015-11-10 | ATG + Busulfan + Fludarabine | Y | N | 220032251 | ATG + BUSULFAN + FLUDARABINE |
| 220017662 | 220008531 | 1.28 | null | Curative (C) | 2017-05-01 | 2017-05-01 | CYCLOPHOSPHAMIDE + FLUDARABINE | 02 | Y | 220032254 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220017663 | 220008531 | 1.7 | 48.5 | Curative (C) | null | 2014-07-04 | BOSUTINIB | N | N | 220032254 | BOSUTINIB |
| 220017665 | 220008537 | 0 | 67.8 | Disease modification (D) | 2016-11-03 | 2016-11-09 | Cyclophosphamide TBI Allograft | N | N | 220032262 | CYCLOPHOSPHAMIDE |